204 related articles for article (PubMed ID: 37045474)
1. Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis.
Moreno-Castaño AB; Fernández S; Ventosa H; Palomo M; Martinez-Sanchez J; Ramos A; Ortiz-Maldonado V; Delgado J; Fernández de Larrea C; Urbano-Ispizua A; Penack O; Nicolás JM; Téllez A; Escolar G; Carreras E; Fernández-Avilés F; Castro P; Diaz-Ricart M
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37045474
[TBL] [Abstract][Full Text] [Related]
2. Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes.
Fernández S; Moreno-Castaño AB; Palomo M; Martinez-Sanchez J; Torramadé-Moix S; Téllez A; Ventosa H; Seguí F; Escolar G; Carreras E; Nicolás JM; Richardson E; García-Bernal D; Carlo-Stella C; Moraleda JM; Richardson PG; Díaz-Ricart M; Castro P
Shock; 2022 Jan; 57(1):95-105. PubMed ID: 34172614
[TBL] [Abstract][Full Text] [Related]
3. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
[TBL] [Abstract][Full Text] [Related]
4. Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy.
Palomo M; Youssef L; Ramos A; Torramade-Moix S; Moreno-Castaño AB; Martinez-Sanchez J; Bonastre L; Pino M; Gomez-Ramirez P; Martin L; Garcia Mateos E; Sanchez P; Fernandez S; Crovetto F; Escolar G; Carreras E; Castro P; Gratacos E; Crispi F; Diaz-Ricart M
Am J Obstet Gynecol; 2022 Aug; 227(2):277.e1-277.e16. PubMed ID: 35351411
[TBL] [Abstract][Full Text] [Related]
5. Endothelial cell activation in cutaneous vasculitis.
Jurd KM; Stephens CJ; Black MM; Hunt BJ
Clin Exp Dermatol; 1996 Jan; 21(1):28-32. PubMed ID: 8689765
[TBL] [Abstract][Full Text] [Related]
6. Molecular Pathogenesis of Endotheliopathy and Endotheliopathic Syndromes, Leading to Inflammation and Microthrombosis, and Various Hemostatic Clinical Phenotypes Based on "Two-Activation Theory of the Endothelium" and "Two-Path Unifying Theory" of Hemostasis.
Chang JC
Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143988
[TBL] [Abstract][Full Text] [Related]
7. Endothelial cell and hemostatic activation in relation to cytokines in patients with sepsis.
López-Aguirre Y; Páramo JA
Thromb Res; 1999 Apr; 94(2):95-101. PubMed ID: 10230894
[TBL] [Abstract][Full Text] [Related]
8. Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells.
Galli E; Sorà F; Hohaus S; Fresa A; Pansini I; Autore F; Metafuni E; Innocenti I; Limongiello MA; Giammarco S; Laurenti L; Bacigalupo A; Chiusolo P; De Stefano V; Sica S
Br J Haematol; 2023 Apr; 201(1):86-94. PubMed ID: 36503182
[TBL] [Abstract][Full Text] [Related]
9. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
10. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
11. Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity.
Schmidts A; Wehrli M; Maus MV
Annu Rev Med; 2021 Jan; 72():365-382. PubMed ID: 32776808
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection.
Francischetti IMB; Toomer K; Zhang Y; Jani J; Siddiqui Z; Brotman DJ; Hooper JE; Kickler TS
EClinicalMedicine; 2021 Sep; 39():101069. PubMed ID: 34377969
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
14. Toxicities associated with adoptive cellular therapies.
Hansen DK; Dam M; Faramand RG
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101287. PubMed ID: 34625233
[TBL] [Abstract][Full Text] [Related]
15. Hematologic Malignancies: Plasma Cell Disorders.
Dhodapkar MV; Borrello I; Cohen AD; Stadtmauer EA
Am Soc Clin Oncol Educ Book; 2017; 37():561-568. PubMed ID: 28561703
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor T Cells in Hematologic Malignancies.
Shank BR; Do B; Sevin A; Chen SE; Neelapu SS; Horowitz SB
Pharmacotherapy; 2017 Mar; 37(3):334-345. PubMed ID: 28079265
[TBL] [Abstract][Full Text] [Related]
17. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E
Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479
[TBL] [Abstract][Full Text] [Related]
18. Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction.
Fogarty H; Ward SE; Townsend L; Karampini E; Elliott S; Conlon N; Dunne J; Kiersey R; Naughton A; Gardiner M; Byrne M; Bergin C; O'Sullivan JM; Martin-Loeches I; Nadarajan P; Bannan C; Mallon PW; Curley GF; Preston RJS; Rehill AM; Baker RI; Cheallaigh CN; O'Donnell JS;
J Thromb Haemost; 2022 Oct; 20(10):2429-2438. PubMed ID: 35875995
[TBL] [Abstract][Full Text] [Related]
19. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
Hay KA; Hanafi LA; Li D; Gust J; Liles WC; Wurfel MM; López JA; Chen J; Chung D; Harju-Baker S; Cherian S; Chen X; Riddell SR; Maloney DG; Turtle CJ
Blood; 2017 Nov; 130(21):2295-2306. PubMed ID: 28924019
[TBL] [Abstract][Full Text] [Related]
20. Toxicities following CAR-T therapy for hematological malignancies.
Hernani R; Benzaquén A; Solano C
Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
